Q32 BioQTTB
About: Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
Employees: 42
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
120% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 10
86% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 21
33% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]
25% more funds holding
Funds holding: 72 [Q3] → 90 (+18) [Q4]
14.72% more ownership
Funds ownership: 75.56% [Q3] → 90.28% (+14.72%) [Q4]
88% less call options, than puts
Call options by funds: $62K | Put options by funds: $498K
91% less capital invested
Capital invested by funds: $406M [Q3] → $37.8M (-$368M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Wells Fargo Derek Archila 39% 1-year accuracy 12 / 31 met price target | 815%upside $15 | Equal-Weight Maintained | 12 Mar 2025 |
BMO Capital Etzer Darout 15% 1-year accuracy 5 / 33 met price target | 83%upside $3 | Market Perform Downgraded | 11 Feb 2025 |
Piper Sandler Christopher Raymond 24% 1-year accuracy 7 / 29 met price target | 144%upside $4 | Neutral Downgraded | 11 Feb 2025 |
Financial journalist opinion









